{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.6","upperLimit":"58.7","value":"50.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a best overall response of either Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions as assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experienced a CR or PR as assessed per RECIST 1.1 by blinded independent central review (BICR) is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-clear cell Renal Cell Carcinoma (nccRCC) received 400 mg Pembrolizumab (Pembro) intravenously (IV) on Day 1 of a 42-day cycle (every 6 weeks (Q6W)) for approximately 2 years PLUS 20 mg Lenvatinib (Lenva) orally once daily (QD) on Days 1 and 22 of a 42-day cycle (Q6W). Participants continued study intervention until progressive disease or discontinuation.","id":"OG000","title":"Pembrolizumab + Lenvatinib"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}